Cynata Therapeutics Limited (ASX: CYP)
Health Care · Biotechnology · AU
AU$0.01
-8.33% today · -95.1% 1Y
Cynata Therapeutics Limited (ASX: CYP) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.86M and employs 0 people.
Over the last twelve months the share price has lost 95.1%, trading between 0.01 and 0.44.
Tweenvest scores Cynata Therapeutics Limited across four factors: quality 21/100, value 41/100. Its strongest factor is value.
CYP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.86M
- Revenue (TTM)
- $1.18M
- P/E
- —
- EPS
- -0.04
- Dividend yield
- —
- Beta (5Y)
- 1.12
- 52-week high
- AU$0.44
- 52-week low
- AU$0.01
- Avg volume (3M)
- —
- Shares outstanding
- 243.45M
- Employees
- 0
- Next earnings
- —
About Cynata Therapeutics Limited
Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal stem cell technology for human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully concluded Phase I clinical trials for graft versus host disease. The company's pipeline also includes CYP-004, currently in Phase III trials for osteoarthritis treatment, and CYP-006TK, an innovative polymer-coated silicon wound dressing designed for diabetic wounds. Furthermore, Cynata is advancing therapies for a broad spectrum of conditions such as asthma, heart attacks, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata maintains a crucial strategic alliance with Fujifilm, which is responsible for the clinical and commercial manufacturing and supply of its Cymerus therapeutic mesenchymal stem cell products.
- ISIN
- AU000000CYP7
- Founded
- 2003
- Listed since
- Dec 19, 2007
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Alaunos Therapeutics, Inc.NasdaqCM: TCRT | $2.08M | $0.78 | -4.76% |
| Abpro Holdings, Inc.OTCPK: ABPO | $2.08M | $0.35 | -13.90% |
| Anatara Lifesciences LtdASX: ANR | $1.97M | AU$0.01 | -10.00% |
| Transgene Biotek LimitedBSE: 526139 | $1.89M | Rs2.40 | -7.69% |
| Neural Therapeutics Inc.CNSX: NURL | $1.80M | CA$0.02 | -25.00% |
| Respiratorius AB (publ)XSAT: RESP | $1.72M | Skr2.19 | +0.92% |
| BioXcel Therapeutics, Inc.OTCPK: BTAI.Q | $1.63M | $0.05 | +35.42% |
| Halberd CorporationOTCPK: HALB | $1.49M | $0.00 | +100.00% |
Figures last refreshed Oct 4, 2026.